Top PBS drug at delisting risk

Posted 26 August 2024 AM 

Negotiations around funding pharmaceuticals is often intense, and usually behind-the-scenes. The outcomes of the July PBAC Meeting gave a rare glimpse at the battle, with a major pharma threatening to pull one of the highest-earning drugs from the PBS.

Sanofi is playing hardball over its request for the PBAC to consider the financial aspects for Dupixent in treating severe atopic dermatitis in patients aged 12 and over, requesting to otherwise delist Dupixent from the PBS for the indication. Dupixent earned $314.8 million in pre-rebate reimbursements from the R/PBS in the 2023 financial year for severe atopic dermatitis, which would likely land it in the top 10 for that indication alone.

To see the whole article, please login